A detailed history of Centerpoint Advisors, LLC transactions in Geron Corp stock. As of the latest transaction made, Centerpoint Advisors, LLC holds 300 shares of GERN stock, worth $876. This represents 0.0% of its overall portfolio holdings.

Number of Shares
300
Previous 300 -0.0%
Holding current value
$876
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 03, 2023

SELL
$2.14 - $3.4 $4,280 - $6,800
-2,000 Reduced 86.96%
300 $1,000
Q4 2022

Jan 24, 2023

BUY
$2.03 - $2.42 $3,450 - $4,114
1,700 Added 283.33%
2,300 $6,000
Q3 2022

Oct 13, 2022

BUY
$1.67 - $2.94 $501 - $882
300 Added 100.0%
600 $1,000
Q1 2021

Apr 23, 2021

SELL
$1.52 - $2.1 $456 - $630
-300 Reduced 50.0%
300 $0
Q2 2020

Jul 31, 2020

BUY
$1.05 - $2.18 $630 - $1,308
600 New
600 $1,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.1B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Centerpoint Advisors, LLC Portfolio

Follow Centerpoint Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centerpoint Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Centerpoint Advisors, LLC with notifications on news.